Clinical trials in type 1 diabetes showed that appropriate dosages of systemic anti-IL-7R Ab treatment selectively inhibited memory T cells while preserving naive T cells or regulatory T cells (Treg), as well as protective memory from past vaccinations.72 This evidence concerns the gene IL7R and type 1 diabetes mellitus.